Vicapsys Life Sciences, Inc. — fact timeline

Vicapsys Life Sciences, Inc. amended debt of $363,000 with AJB Capital Investments, LLC maturing January 27, 2024.

“extend the Maturity Date of the Note to January 27, 2024, (ii) increase the Principal of the Note to $363,000”

Vicapsys Life Sciences, Inc. incurred loan of $330,000 with AJB Capital Investments, LLC at 10% a year maturing December 27, 2023.

“On June 27, 2023, we entered into a securities purchase agreement (the “SPA”) with AJB Capital Investments, LLC (“AJB”) and issued a promissory note in the principal amount of $330,000 (the “note”) to AJB pursuant to the SPA for an purchase price of $303,600.”

Vicapsys Life Sciences, Inc. entered into SPA with AJB Capital Investments, LLC valued at principal amount of $330,000 (effective 2023-06-27).

“On June 27, 2023, we entered into a securities purchase agreement (the "SPA") with AJB Capital Investments, LLC ("AJB") and issued a promissory note in the principal amount of $330,000 (the "note") to AJB pursuant to the SPA for an purchase price of $303,600.”

Vicapsys Life Sciences, Inc. amended Ninth Amendment to the Exclusive Patent License Agreement with The General Hospital Corporation d/b/a Massachusetts General Hospital (effective 2023-03-31).

“On March 31, 2023, Vicapsys Life Sciences, Inc.(the “Company”) and The General Hospital Corporation d/b/a Massachusetts General Hospital (the “Hospital”) entered into a Ninth Amendment to the Exclusive Patent License Agreement (the “Ninth Amendment”).”

Vicapsys Life Sciences, Inc. engaged Assurance Dimensions. as its auditor.

“On May 12, 2023, 2023, the Board appointed Assurance Dimensions. (“Assurance”) as the Company’s independent registered public accounting firm to audit the Company’s consolidated financial statements for the fiscal year ending December 31, 2023.”

Vicapsys Life Sciences, Inc. dismissed D. Brooks and Associates CPAs, P.A. as its auditor.

“On May 12, 2023, the Board of Directors (the “Board”) of the Vicapsys Life Sciences, Inc. (the “Company”) approved the dismissal of D. Brooks and Associates CPAs, P.A. (“D. Brooks”) as the Company’s independent registered public accounting firm effective May 12, 2023.”

Vicapsys Life Sciences, Inc. engaged Assurance Dimensions as its auditor.

“the Board appointed Assurance Dimensions. (“Assurance”) as the Company’s independent registered public accounting firm to audit the Company’s consolidated financial statements for the fiscal year ending December 31, 2023.”

Vicapsys Life Sciences, Inc. dismissed D. Brooks and Associates CPAs, P.A. as its auditor.

“the Board of Directors (the “Board”) of the Vicapsys Life Sciences, Inc. (the “Company”) approved the dismissal of D. Brooks and Associates CPAs, P.A. (“D. Brooks”) as the Company’s independent registered public accounting firm effective May 12, 2023.”

Richard Rosenblum was appointed as director at Vicapsys Life Sciences, Inc..

“appointed each of Charles “Charlie” Farrahar, Dr. Colleen Delaney and Richard Rosenblum as members of the Board.”

Colleen Delaney was appointed as director at Vicapsys Life Sciences, Inc..

“appointed each of Charles “Charlie” Farrahar, Dr. Colleen Delaney and Richard Rosenblum as members of the Board.”

Charles Farrahar was appointed as director at Vicapsys Life Sciences, Inc..

“appointed each of Charles “Charlie” Farrahar, Dr. Colleen Delaney and Richard Rosenblum as members of the Board.”

Michael Yurkowsky resigned as director at Vicapsys Life Sciences, Inc..

“accepted the resignations of John Potts and Michael Yurkowsky as members of the Board, effective immediately.”

John Potts resigned as director at Vicapsys Life Sciences, Inc..

“accepted the resignations of John Potts and Michael Yurkowsky as members of the Board, effective immediately.”

Federico Pier was appointed as Chief Executive Officer at Vicapsys Life Sciences, Inc..

“On February 15, 2022, the Board of Directors (the “Board”) of Vicapsys Life Sciences, Inc. (the “Company”) appointed Federico Pier as Chief Executive Officer of the Company.”